Business Wire

Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes

Share

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VX-880 and that the company has initiated a clinical trial for VX-880 in patients who have type 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness.

“This program has its roots in the groundbreaking work that began in Dr. Doug Melton’s lab, progressed at Semma Therapeutics, and has been accelerated and brought to the clinic by the team at Vertex,” said Bastiano Sanna, Ph.D., Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. “Ours is the only approach that produces fully differentiated and fully functional insulin-secreting pancreatic islets. We are very pleased to have received FDA’s Fast Track Designation, which facilitates the development and expedites the review of drugs that treat serious conditions and fill an unmet medical need. We continue to work with urgency to bring this innovative therapy to patients.”

“It’s a remarkable time for T1D research efforts worldwide, as this investigational treatment enters the clinic,” said Camillo Ricordi, M.D., Professor of Surgery, Director of the Diabetes Research Institute (DRI) and the Cell Transplant Center at the University of Miami Miller School of Medicine, and Steering Committee Chair for the VX-880 clinical trial. “The field’s experience with the limited cadaveric islet transplants available, where some patients have experienced prolonged insulin independence for years, provides important proof-of-concept for the potential of cell therapy to be transformative for patients living with T1D.”

The first clinical trial sites at the University of Miami Health System, the University of Pennsylvania and Massachusetts General Hospital are open for enrollment, and additional sites will be activated this year. To learn more visit clinicaltrials.gov.

About VX-880

VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including insulin production.

The VX-880 clinical trial will involve an infusion of fully differentiated, functional islet cells, as well as the chronic administration of concomitant immunosuppressive therapy, to protect the islet cells from immune rejection.

About the Phase 1/2 Clinical Trial

The clinical trial is a Phase 1/2, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. This will be a sequential, multi-part clinical trial to evaluate the safety and efficacy of different doses of VX-880. Approximately 17 patients will be enrolled in the clinical trial.

About Type 1 Diabetes

T1D results from the autoimmune destruction of insulin-producing islet cells in the pancreas, leading to loss of insulin production and impairment of blood glucose control. The absence of insulin leads to abnormalities in how the body processes nutrients, leading to high blood glucose levels. High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death.

Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in patients with T1D. Hypoglycemia often results because of the difficulty in balancing the different factors that impact glucose levels, including insulin, diet and exercise. Hypoglycemia remains a critical limiting factor in glycemic management, and severe hypoglycemia can cause loss of consciousness, coma, seizures, injury, and can be fatal. Over time, patients with T1D can develop impaired awareness of hypoglycemia, meaning they are no longer able to perceive the early signs of a hypoglycemic event, which can be dangerous and result in life threatening events.

There are currently limited treatment options beyond insulin for the management of T1D.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Dr. Bastiano Sanna and Dr. Camillo Ricordi in this press release, statements regarding the development, plans and expectations for our T1D pipeline program, including our Phase 1/2 clinical trial in people with T1D, statements regarding patient enrollment, dosing and activation of new sites, statements regarding potential clinical trial results and anticipated benefits of VX-880, and our plans to provide further updates on our T1D pipeline program. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the FDA may not approve our IND, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's development programs may not support registration or further development due to safety, efficacy or other reasons, that the COVID-19 pandemic may impact the status or progress of our clinical trial of VX-880, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Contact information

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, +1 617-341-6108
or
Brenda Eustace, +1 617-341-6187
or
Manisha Pai, +1 617-429-6891

Media:
mediainfo@vrtx.com
or
U.S.: +1 617-341-6992
or
Heather Nichols: +1 617-839-3607
or
International: +44 20 3204 5275

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SHINE, Phoenix merger focused on advancing fusion technology20.4.2021 21:00:00 EEST | Press release

SHINE Medical Technologies LLC and Phoenix LLC today announced that the companies have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420006038/en/ Greg Piefer, CEO of SHINE (left), talks with Evan Sengbusch, general manager of SHINE's Phoenix division, and Ross Radel, chief technology officer and chief operating officer of the Phoenix division, at the Phoenix headquarters and manufacturing center in Fitchburg, Wis., on April 16, 2021. (Photo: SHINE Medical Technologies) SHINE is a next-generation nuclear technology company focused on unlocking the power of fusion technologies to benefit the planet and humankind. The company’s goal is to deliver on the long-term promise of clean fusion energy by advancing fusion technology starting with the commercialization of medical isotopes. Phoenix designs and manufactures the world’s strongest stea

Hilton Releases 2020 ESG Report, Reinforcing Commitment to Positive Global Impact20.4.2021 18:49:00 EEST | Press release

Hilton (NYSE: HLT) has released its 2020 Environmental, Social and Governance (ESG) Report, which highlights the company’s continued commitment to redefining sustainable travel and driving positive impact on people and the planet. Through Hilton’s Travel with Purpose program, the company continues to take important steps to integrate positive social impact and environmental stewardship throughout its operations, communities and supply chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005911/en/ Hilton releases 2020 ESG report, reinforcing commitment to positive global impact. (Photo: Business Wire) “As we weathered this unpredictable year, Hilton has remained focused on our Team Members and the communities we serve around the world,” said Kristin Campbell, general counsel and chief ESG officer, Hilton. “We took a nimble approach during this difficult period to deliver meaningful support, while remaining focused on

Xsolla Unifies Skill-Based Gaming and Esports Platform, Monetization and Subscription Programs20.4.2021 17:30:00 EEST | Press release

Xsolla, the video game commerce company powered by its Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, has launched their new esports solution, enabling video game developers, publishers, and esports event producers to create engaging fan experiences with safe and secure payment processing, globally. The new program provides a straightforward, streamlined solution for the fastest growing entertainment segment worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005530/en/ Xsolla Unifies Skill-Based Gaming and Esports Platform, Monetization and Subscription Programs (Graphic: Business Wire) With Xsolla’s full suite of products, companies can work with esports properties or build their own esports platform with streamlined payments and subscriptions plans. With programs that scale from small local skill-based matchups to massive global

The Federation of Royal Colleges of Physicians Approves UpToDate Clinical Decision Support for CPD20.4.2021 16:30:00 EEST | Press release

UpToDate, the clinical decision support tool from Wolters Kluwer, Health has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom as a continuing professional development (CPD) activity. The organization is a collaboration between the Royal College of Physicians of London, Royal College of Physicians of Edinburgh, and Royal College of Physicians and Surgeons of Glasgow. The colleges have more than 50,000 members among them worldwide. The approval of UpToDate comes following new guidelines introduced by the Federation that recognize the use of online resources with current medical content (e-libraries) as CPD. Earning CPD while caring for patients Members will now be able to earn and track credits eligible for continuing professional development while using UpToDate to research clinical questions at the point of care. CPD credits are earned from UpToDate by consulting information relevant to a specific clinical question, thus broadening clinical know

MSCI Calls on Capital to Lead the Net-Zero Revolution20.4.2021 16:21:00 EEST | Press release

Addressing climate change will require the largest reconstruction of the global economy since the Industrial Revolution, according to a report published today by MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community. ‘The Role of Capital in the Net-Zero Revolution’ highlights how capital markets participants must be a powerful and positive force to urgently drive the systemic transformation needed to avert climate catastrophe. This call to action identifies specific steps that companies as well as owners and managers of capital must take to drive the achievement of a net-zero economy by 2050. Analysis by MSCI of its All Country World Investable Markets Index (MSCI ACWI IMI) - a measure of approximately 9,000 publicly listed companies across 50 developed and emerging markets with a market value of over USD 70 trillion1 – revealed those companies annually emit an estimated 11.2 gigatons of carbon dioxide equivalent

PPG Reports Increased Sales of Sustainably Advantaged Products, Continued Progress on Sustainability Goals20.4.2021 16:04:00 EEST | Press release

PPG (NYSE:PPG) today launched its 2020 Sustainability Report, highlighting the company’s strong, continued progress against key environmental, social and governance (ESG) areas. The report is available at sustainability.ppg.com. “Our unwavering commitment to ‘protect and beautify the world’ guides our more than 46,000 employees to further advance our sustainability progress each day,” said Michael H. McGarry, PPG chairman and chief executive officer. “We continue to innovate, invest and develop sustainably advantaged products and processes that our customers and other stakeholders count on to create a more sustainable future. As highlighted in our latest Sustainability Report, we have made significant progress within our many ESG-related initiatives, and we continue to drive our ambitious targets forward.” Throughout last year, PPG improved the sustainability of its products, processes and operations, decreasing its overall global environmental footprint. Achievements included: 35% of

Magnitude Introduces Cloud-Scale Business Insights for ERP Systems20.4.2021 16:00:00 EEST | Press release

Magnitude Software, provider of continuous intelligence for the data-driven enterprise, today announced the release of Magnitude Angles Cloud, a cloud-based version of the company’s Angles process analytics solution. Angles Cloud greatly accelerates the delivery of powerful business insights from SAP and Oracle ERP systems directly to operational leaders in finance, supply chain, manufacturing and distribution, enabling them to make faster, more effective business decisions. Traditional business intelligence reporting requires custom development by teams of data scientists, skilled in translating the complex data schema of ERP systems, to build reports consumable by business users. Magnitude Angles provides a context-rich business data model that abstracts this complexity and includes thousands of pre-configured templates and reports to put operational analytics in the hands of business users. By eliminating the need for time-consuming custom development to provide near real-time busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom